Chart: Health Care Reform: Where Is It Now?
You may also be interested in...
The House health care reform bill asks pharmaceutical manufacturers to pay their share of the cost of expanding health care coverage by paying higher rebates on more drugs
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials